GKP Blend
GHK-Cu 50 mg, KPV 10 mg and BPC-157 10 mg co-lyophilized in one vial, a blue three-peptide research blend. Every lot is tested in the manufacturer’s own laboratory and has a certificate.
| Components | GHK-Cu (Copper tripeptide-1; Gly-His-Lys · Cu(II))KPV (Lys-Pro-Val; α-MSH(11–13))BPC-157 (Body Protection Compound-157; pentadecapeptide) |
|---|---|
| GHK-Cu CAS number | 89030-95-5 |
| KPV CAS number | 67727-97-3 |
| BPC-157 CAS number | 137525-51-0 |
| Label claim | GHK-Cu 50 mg + KPV 10 mg + BPC-157 10 mg (70 mg in total) |
| Form | Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap |
| Storage, sealed | −20 °C, desiccated, dark |
| Purity specification | 99.0% or higher by RP-HPLC |
| Format | Lyophilized powder, sealed vial |
Sizes and lots
- 70 mg · 1 vial — $296.50 · lot PL-2609-041, certificate PL-26-00041
- 70 mg · Kit of 10 — $2635.89 · lot PL-2609-041, certificate PL-26-00041
GKP is a three-peptide research blend: GHK-Cu, the copper complex of the tripeptide Gly-His-Lys, with the alpha-MSH fragment KPV and the gastric pentadecapeptide BPC-157. This 70 mg vial holds 50, 10 and 10 mg of them as one blue freeze-dried cake. There is no published research on GKP as a blend. The studies summarised here concern each peptide alone: fibroblast matrix work, intestinal cells and colitis models, and gut, tendon and vascular injury in rats.
What is in the vial
The certificate confirms three components by LC-MS: GHK-Cu (H-GHK-OH with Cu(II), 401.9 Da), KPV (H-KPV-OH, 342.4 Da) and BPC-157 (H-GEPPPGKPADDAGLV-OH, 1419.6 Da). Two of the three are tripeptides, so the molar picture differs from the mass ratio: 50 mg of GHK-Cu is about 124 µmol, 10 mg of KPV about 29 µmol and 10 mg of BPC-157 about 7.0 µmol. There are roughly four GHK-Cu molecules for every KPV molecule, and about four KPV molecules for every BPC-157.
GKP is the KLOW composition without TB-500, or GLOW 70 mg with KPV in place of thymosin beta-4. The cake and its solutions are blue because of the copper complex. The same three peptides in the same 5:1:1 mass ratio are sold as a ready-made GKP preloaded pen.
What the research covers
No published study has examined GKP, or GHK-Cu, KPV and BPC-157 given together, so nothing is known about the three as a combination. The literature below deals with each peptide on its own.
GHK-Cu
GHK was isolated from human plasma and binds copper(II)1. In cultured fibroblasts the copper complex increased collagen synthesis from picomolar concentrations, with a peak at 1 nanomolar and no rise in cell numbers1. The authors also pointed out that the GHK sequence is found within type I collagen and might be released from it by proteases at a wound1.
KPV
KPV is the tripeptide Lys-Pro-Val, residues 11 to 13 of alpha-melanocyte-stimulating hormone2. Dalmasso and colleagues tested it on human intestinal epithelial cells and Jurkat T cells exposed to inflammatory cytokines: at nanomolar concentrations it inhibited NF-κB and MAP kinase signalling and reduced the release of pro-inflammatory cytokines3. Their study also asked whether the effect required uptake through PepT1, a di- and tripeptide transporter that is induced in the colon during inflammatory bowel disease3. Kannengiesser and colleagues used two mouse models of colitis, one induced chemically with dextran sodium sulfate and one by T-cell transfer2. In the chemical model, KPV-treated mice recovered earlier and regained more body weight, and their colons showed fewer inflammatory infiltrates and lower myeloperoxidase activity; in the transfer model, treated mice also recovered2.
BPC-157
BPC-157 is a 15-residue partial sequence of a protein isolated from human gastric juice4. Sikiric and colleagues reviewed its effects in rats on lesions of the esophagus, stomach, duodenum, intestine, liver and pancreas, including alcohol- and NSAID-induced injury, and reported angiogenic and endothelium-protective activity5. In rats with esophagitis it brought lower esophageal and pyloric sphincter pressure back towards normal, and the review also describes it healing intestinal anastomoses and several kinds of fistula5.
Mechanistic work from other laboratories looked at cells. Hsieh and colleagues found that BPC-157 raised vessel density in the chick chorioallantoic membrane and in endothelial tube assays, sped blood-flow recovery in ischemic rat hind limbs, and increased VEGFR2, with downstream Akt and eNOS activation, in human endothelial cells6. Chang and colleagues reported faster outgrowth from rat Achilles tendon explants and more migration, spreading and stress survival in tendon fibroblasts, together with F-actin formation and phosphorylation of FAK and paxillin; proliferation was not directly affected4.
What is not established
Everything here is cell or rodent work, apart from the BPC-157 review's statement that the peptide was safe in inflammatory bowel disease clinical trials, which the abstract does not back with results5. Much of the BPC-157 animal literature comes from one research group. The idea behind the blend, combining peptides studied for matrix repair, inflammation and blood vessel growth, has not itself been tested. None of the papers used SCALE Performance material. The KLOW peptide guide covers GHK-Cu, KPV and BPC-157 in more depth.
Frequently asked questions
What is in GKP 70 mg?
GHK-Cu 50 mg, KPV 10 mg and BPC-157 10 mg, freeze-dried together into one vial. The certificate for the lot confirms all three by LC-MS and reports purity, water content, endotoxin and sterility. The cake is blue because of the copper complex in GHK-Cu.
How does GKP relate to KLOW and GLOW?
All three share 50 mg of GHK-Cu and 10 mg of BPC-157. KLOW adds TB-500 and KPV, GLOW 70 mg adds TB-500 only, and GKP adds KPV only. That makes GKP the one blend of the three without thymosin beta-4.
Has the GKP combination been tested?
No. The published studies cover GHK-Cu, KPV and BPC-157 one at a time, in cell lines, mouse colitis models and rats. Nobody has reported the three together, so interactions and any combined effect are unknown.
What do the molar amounts look like?
About 124 µmol of GHK-Cu, 29 µmol of KPV and 7 µmol of BPC-157, calculated from the certificate's theoretical masses. The real values are slightly lower because the powder holds some water, which the certificate reports as a percentage.
How should the vial be stored?
Sealed at −20 °C, dry and dark, then warmed to room temperature before opening so no condensation forms. Reconstituted solution goes to 2 to 8 °C, protected from light, for a period your laboratory has established.
References
- Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. DOI · PubMed
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31. DOI · PubMed
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. DOI · PubMed
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. DOI · PubMed
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. DOI · PubMed
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. DOI · PubMed
For laboratory research use only. Not for human or veterinary consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.